<DOC>
	<DOCNO>NCT03028909</DOCNO>
	<brief_summary>The purpose study determine MEDI8852 administer standard care ( oseltamivir ) reduce time normalization respiratory function adult hospitalize influenza cause Type A strain determine MEDI8852 acceptable safety profile adult hospitalize influenza cause Type A strain .</brief_summary>
	<brief_title>Dose Ranging Study Evaluate Efficacy Safety MEDI8852 Adults Who Are Hospitalized With Type A Influenza .</brief_title>
	<detailed_description>The MEDI8852 phase 2b study evaluate efficacy safety single intravenous ( IV ) dose MEDI8852 placebo administer conjunction oseltamivir adult subject hospitalize influenza cause Type A strain . Approximately 450 subject enrol study center North America , Europe , region .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Sprains Strains</mesh_term>
	<mesh_term>Oseltamivir</mesh_term>
	<criteria>Age 18 year old time screen . Written inform consent locally require authorization ( eg , Health Insurance Portability Accountability Act [ HIPAA ] United States , Data Privacy Directive Europe ) obtain subject/legal representative prior perform protocol related procedure , include screen evaluation . Females childbearing potential sexually active nonsterilized male partner must evidence pregnant upon enrollment negative pregnancy test prior administration investigational product . Females childbearing potential define surgically sterile ( ie , bilateral tubal ligation , bilateral oophorectomy , complete hysterectomy ) , premenarchal , postmenopausal ( defined 12 month menses without alternative medical cause ) . Hospitalized ≤ 72 hour prior receipt positive diagnostic test influenza A ; confirm positive rapid antigen test ( supply approve sponsor ) , confirmed culture , polymerase chain reaction , antigen test study site . Onset influenza symptom ≤ 144 hour ( ≤ 6 day ) prior randomization . Receiving supplemental oxygen . Expected participate study Day 60 . Any condition , opinion investigator , would interfere evaluation study drug interpretation subject safety study result . Concurrent enrollment another clinical study involve investigational treatment . Hospitalized &gt; 72 hour ( &gt; 3 day ) prior receipt positive diagnostic test influenza A . Receipt &gt; 72 hour &gt; 6 dos treatment neuraminidase ( NA ) inhibitor . Receipt investigational antiviral medication within 30 day prior study drug dosing . Previous receipt influenza mAb within past 100 day . Pregnant nursing female . History allergic disease reaction likely exacerbate component study drug ( MEDI8852 oseltamivir ) . Diagnosis influenza B infection within 14 day prior randomization . Employees sponsor , clinical study site , individual involve conduct study , immediate family member individual .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Influenza A</keyword>
	<keyword>MEDI8852</keyword>
</DOC>